Scientific and Regulatory Approach to Botanical Drug Development: A U.S. FDA Perspective
Charles Wu(Center for Drug Evaluation and Research), Katherine M. Tyner(Center for Drug Evaluation and Research), Yen-Ming Chan(Center for Drug Evaluation and Research), Rajiv Agarwal(Richard L. Roudebush VA Medical Center), Jing Li(Hubei Provincial Center for Disease Control and Prevention), Robert Temple(United States Food and Drug Administration), Cassandra Taylor(Center for Drug Evaluation and Research), Douglas C. Throckmorton(United States Food and Drug Administration), Lee Su-Lin(Center for Drug Evaluation and Research)
Cited by 112
Related Papers
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2020|2.6k
Drug Interaction Studies: Study Design, Data Analysis, and Implications for Dosing and Labeling
|Clinical Pharmacology & Therapeutics|2007|582
Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium
|Nature Biotechnology|2010|406
Cardiovascular complications in chronic kidney disease: a review from the European Renal and Cardiovascular Medicine Working Group of the European Renal Association
|Cardiovascular Research|2023|312
Pulmonary Hypertension in CKD
|American Journal of Kidney Diseases|2012|178